Patrick Ouzts, MD
Sports Medicine · Oro Valley, AZNPI 1528590163
Payments from drug & device makers
Across 101 payments — averaging $18.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$303
- Amgen$169
- GSK$156
- Teva Pharmaceuticals USA, Inc.$120
- AbbVie$117
- Pfizer$116
- plus $898 from 20 others
What the payments were for
- Food & beverage$1,878100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 17 | $303 |
| Amgen | 10 | $169 |
| GSK | 9 | $156 |
| Teva Pharmaceuticals USA, Inc. | 6 | $120 |
| AbbVie | 6 | $117 |
| Pfizer | 7 | $116 |
| Astellas Pharma US Inc | 5 | $106 |
| Johnson & Johnson | 5 | $84 |
| Novo Nordisk | 4 | $84 |
| Exact Sciences | 4 | $70 |
| Sumitomo Pharma America, Inc. | 3 | $69 |
| Novartis | 3 | $59 |
| Lilly USA, LLC | 3 | $47 |
| Boehringer Ingelheim | 2 | $41 |
| Merck | 2 | $41 |
| Boston Scientific | 1 | $40 |
| Aimmune Therapeutics, Inc. | 2 | $38 |
| Idorsia Pharmaceuticals US Inc | 2 | $36 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $33 |
| Bayer | 2 | $33 |
| Abbott | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Lundbeck LLC | 1 | $21 |
| Eisai Inc. | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Nestle Healthcare Nutrition Inc. | 1 | $13 |
How this compares
$1,878 in reported general payments places this provider in the 50th percentile of 152 sports medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 72 | $82,575 |
| JardianceEmpagliflozin | 78 | $80,905 |
| OzempicSemaglutide | 61 | $73,548 |
| MounjaroTirzepatide | 56 | $69,532 |
| TrulicityDulaglutide | 49 | $58,184 |
| XareltoRivaroxaban | 36 | $57,363 |
| MyrbetriqMirabegron | 43 | $36,683 |
| JanuviaSitagliptin Phosphate | 27 | $35,374 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $22,703 |
| FarxigaDapagliflozin Propanediol | 12 | $17,927 |
| SymbicortBudesonide/Formoterol Fumarate | 52 | $16,325 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $11,742 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $10,435 |
| Atorvastatin Calcium | 960 | $7,432 |
| PremarinEstrogens, Conjugated | 14 | $7,060 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $47 | $127,716105 claims |
| PfizerEliquis, Premarin, Paxlovid | $116 | $93,923110 claims |
| Boehringer IngelheimJardiance | $41 | $80,90578 claims |
| Novo NordiskOzempic | $84 | $73,54861 claims |
| Johnson & JohnsonXarelto | $84 | $57,36336 claims |
| AstraZenecaFarxiga, Symbicort, Breztri Aerosphere, Pulmicort Flexhaler | $303 | $48,89096 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $156 | $38,56154 claims |
| Astellas Pharma US IncMyrbetriq | $106 | $36,68343 claims |
| MerckJanuvia | $41 | $35,37427 claims |
| AbbVieSynthroid | $117 | $5,64094 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 152 sports medicine providers in Arizona.
Other sports medicine in Oro Valley
- Thomas FielTempe$23.5M
- Anup ShahPhoenix$1.5M
- Amon FerryScottsdale$752K
- John TokishScottsdale$611K
- Eric EiflerChandler$342K
- John BrownSun City West$289K
- Shelden MartinChandler$208K
- Kyle ChunPrescott Valley$160K
- Matthew HansenGilbert$84K
- Jeffrey AbildgaardGilbert$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.